High rates of hepatocellular carcinoma within two years of starting treatment for chronic hepatitis C with direct antiviral agents but not with PEG-interferon/ Ribavirin (HORRID Study)
Fatih Karbeyaz(University Hospital Zurich), Alexander Siebenhuener(University Hospital Zurich), Beat Müllhaupt(University Hospital of Zurich), Benjamin Misselwitz(University of Zurich), Thomas Winder, Joachim C. Mertens(GastroZentrum Hirslanden Zürich)
Cited by 0
Related Papers
Cholangiocarcinoma 2020: the next horizon in mechanisms and management
|Nature Reviews Gastroenterology & Hepatology|2020|2.5k
Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)
|Nature Reviews Gastroenterology & Hepatology|2016|1.4k
Prognosis of patients with hepatocellular carcinoma treated with immunotherapy – development and validation of the CRAFITY score
|Journal of Hepatology|2021|309